Martina Orfei1, Marco Gasparetto1, Kai O Hensel1,2, Florian Zellweger3,4, Robert B Heuschkel1, Matthias Zilbauer1,5. 1. Department of Paediatric Gastroenterology, Hepatology and Nutrition, Cambridge University Hospitals, Cambridge, United Kingdom. 2. Department of Paediatrics, Faculty of Health, University Witten/Herdecke, Centre for Clinical and Translational Research, Witten, Germany. 3. Department of Plant Sciences, University of Cambridge, Cambridge, United Kingdom. 4. Swiss Federal Research Institute WSL, Birmensdorf, Switzerland. 5. Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom.
Abstract
BACKGROUND: Faecal calprotectin (FCP) is a powerful tool to predict inflammatory bowel disease (IBD) in patients with gastrointestinal symptoms. In the paediatric patient population, the reference value of < 50 μg/g and the influence of age on FCP levels result in a high number of redundant investigations and specialist referrals. We assessed paediatric FCP levels, their diagnostic value and corresponding referral pathways from primary and secondary care. METHODS: We analysed two cohorts from a precisely defined catchment area: one consisted of all FCPs measured in this area (n = 2788). The second cohort-a subset of the first cohort-consisted of FCP values and corresponding clinical data from children who were referred for possible IBD to our department (n = 373). RESULTS: In the first cohort, 47% of FCP levels were > 50 μg/g, 15% were ≥ 250 μg/g. Children < 1y had significantly (p < 0.001) higher FCP than older children. In the second cohort, 6.7% of children with an FCP of < 250 μg/g (or 8.6% with an FCP of < 600 μg/g) had IBD-all featured symptoms suggestive of IBD (e.g. bloody diarrhoea, nocturnal abdominal pain, weight loss) or abnormal blood tests. 76% of patients in whom raised FCP (> 50 μg/g) was the sole reason for being referred for suspected IBD did not have IBD. CONCLUSION: Children with an FCP < 600 μg/g and without matching symptoms suggestive of IBD are unlikely to have IBD. A higher FCP reference value may provide cost-effective improvement that could avoid redundant investigations and specialist referrals. A guideline for specialist referrals is proposed.
BACKGROUND: Faecal calprotectin (FCP) is a powerful tool to predict inflammatory bowel disease (IBD) in patients with gastrointestinal symptoms. In the paediatric patient population, the reference value of < 50 μg/g and the influence of age on FCP levels result in a high number of redundant investigations and specialist referrals. We assessed paediatric FCP levels, their diagnostic value and corresponding referral pathways from primary and secondary care. METHODS: We analysed two cohorts from a precisely defined catchment area: one consisted of all FCPs measured in this area (n = 2788). The second cohort-a subset of the first cohort-consisted of FCP values and corresponding clinical data from children who were referred for possible IBD to our department (n = 373). RESULTS: In the first cohort, 47% of FCP levels were > 50 μg/g, 15% were ≥ 250 μg/g. Children < 1y had significantly (p < 0.001) higher FCP than older children. In the second cohort, 6.7% of children with an FCP of < 250 μg/g (or 8.6% with an FCP of < 600 μg/g) had IBD-all featured symptoms suggestive of IBD (e.g. bloody diarrhoea, nocturnal abdominal pain, weight loss) or abnormal blood tests. 76% of patients in whom raised FCP (> 50 μg/g) was the sole reason for being referred for suspected IBD did not have IBD. CONCLUSION:Children with an FCP < 600 μg/g and without matching symptoms suggestive of IBD are unlikely to have IBD. A higher FCP reference value may provide cost-effective improvement that could avoid redundant investigations and specialist referrals. A guideline for specialist referrals is proposed.
Authors: Judith Zeevenhooven; Robyn Rexwinkel; Ellen Tromp; Bart Haver; Michael Groeneweg; Marc A Benninga; Arine M Vlieger Journal: J Pediatr Date: 2020-01-24 Impact factor: 4.406
Authors: Ioannis D Kostakis; Kyriaki G Cholidou; Aristeidis G Vaiopoulos; Ioannis S Vlachos; Despina Perrea; George Vaos Journal: Dig Dis Sci Date: 2012-08-17 Impact factor: 3.199
Authors: María Roca; Ana Rodriguez Varela; Ester Donat; Francisco Cano; David Hervas; Ana Armisen; Maria J Vaya; Anders Sjölander; Carmen Ribes-Koninckx Journal: J Pediatr Gastroenterol Nutr Date: 2017-10 Impact factor: 2.839
Authors: Anthony Buisson; Wing Yan Mak; Michael J Andersen; Donald Lei; Stacy A Kahn; Joel Pekow; Russel D Cohen; Nada Zmeter; Bruno Pereira; David T Rubin Journal: J Crohns Colitis Date: 2019-08-14 Impact factor: 9.071
Authors: Gea A Holtman; Yvonne Lisman-van Leeuwen; Andrew S Day; Ulrika L Fagerberg; Paul Henderson; Stevan T Leach; Gøri Perminow; David Mack; Patrick F van Rheenen; Els van de Vijver; David C Wilson; Johannes B Reitsma; Marjolein Y Berger Journal: JAMA Pediatr Date: 2017-10-01 Impact factor: 26.796
Authors: Pieter L J Degraeuwe; Monique P A Beld; Merja Ashorn; Roberto Berni Canani; Andrew S Day; Antonella Diamanti; Ulrika L Fagerberg; Paul Henderson; Kaija-Leena Kolho; Els Van de Vijver; Patrick F van Rheenen; David C Wilson; Alfons G H Kessels Journal: J Pediatr Gastroenterol Nutr Date: 2015-03 Impact factor: 3.288
Authors: Anke Heida; Els Van de Vijver; Don van Ravenzwaaij; Stephanie Van Biervliet; Thalia Z Hummel; Zehre Yuksel; Gieneke Gonera-de Jong; Renate Schulenberg; Anneke Muller Kobold; Patrick Ferry van Rheenen Journal: Arch Dis Child Date: 2018-03-07 Impact factor: 3.791
Authors: Arie Levine; Sibylle Koletzko; Dan Turner; Johanna C Escher; Salvatore Cucchiara; Lissy de Ridder; Kaija-Leena Kolho; Gabor Veres; Richard K Russell; Anders Paerregaard; Stephan Buderus; Mary-Louise C Greer; Jorge A Dias; Gigi Veereman-Wauters; Paolo Lionetti; Malgorzata Sladek; Javier Martin de Carpi; Annamaria Staiano; Frank M Ruemmele; David C Wilson Journal: J Pediatr Gastroenterol Nutr Date: 2014-06 Impact factor: 3.288